Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Asset disposition
CLINICAL DATA INC (CLDA) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/18/2011 8-K Quarterly results
04/04/2011 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment No. 1, by and among Clinical Data, Inc., FL Holding CV, Magnolia Acquisition Corp and Forest Laboratories, Inc"
02/25/2011 8-K Form 8-K - Current report
02/22/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Forest Laboratories to Host Conference Call Today at 10:00 AM"
02/09/2011 8-K Form 8-K - Current report
01/27/2011 8-K Form 8-K - Current report
01/24/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Clinical Data, Inc. Announces FDA Approval of Viibryd™ for Major Depressive Disorder Conference Call to Discuss FDA Approval Monday, January 24 at 8:30 am EST"
01/12/2011 8-K Form 8-K - Current report
01/05/2011 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Fin...
Docs: "AMENDMENT TO ASSET PURCHASE AGREEMENT",
"Secured Promissory Note, issued by Transgenomic, Inc. to PGxHealth, LLC",
"Secured Promissory Note, issued by Transgenomic, Inc. to PGxHealth, LLC",
"Security Agreement, by and between PGxHealth, LLC and Transgenomic, Inc",
"Noncompetition and Nonsolicitation Agreement, by and among PGxHealth, LLC, Clinical Data, Inc. and Transgenomic, Inc",
"Clinical Data, Inc. Closes Sale of FAMILION ® Testing and Pharmacogenomics Biomarker Development Business to Transgenomic, Inc. - Completes Transformation into a Pharmaceutical Company with Promising Late-stage Assets, Including Vilazodone with a PDUFA Date in January 2011"
12/03/2010 8-K Form 8-K - Current report
11/29/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Clinical Data, Inc. to Sell FAMILION ® Testing and Pharmacogenomics Biomarker Development Business for $15.4 Million Plus Potential Milestones, Royalties and other Consideration"
11/09/2010 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Clinical Data, Inc. Reports Second Quarter Fiscal Year 2011 Operational and Financial Results - Preparations Ongoing for Anticipated Launch of Vilazodone with Continued Focus on Phase III Trials of Stedivaze -"
09/22/2010 8-K Form 8-K - Current report
08/09/2010 8-K Form 8-K - Current report
06/14/2010 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Clinical Data, Inc. Reports Fourth Quarter and Fiscal Year 2010 Results — Vilazodone NDA Accepted; January 22, 2011 PDUFA Date Assigned — — Recent Public Offering to Fund Commercial Preparations and Late-stage Programs"
06/09/2010 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement by and among Clinical Data, Inc. and BMO Capital Markets, Corp., Wedbush Morgan Securities, Inc. and Roth Capital Partners, LLC",
"Opinion of Cooley LLP",
"Clinical Data, Inc. Prices Public Offering of Common Stock"
06/08/2010 8-K Form 8-K - Current report
06/07/2010 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "AMENDED AND RESTATED UVAPF/PGx LICENSE AGREEMENT"
05/25/2010 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Clinical Data, Inc. Announces Vilazodone Data Featured at the 2010 American Psychiatric Association and Society of Biological Psychiatry Annual Meetings",
"Poster entitled “Efficacy and Tolerability of Vilazodone, a Dual-Acting Serotonergic Antidepressant, in the Treatment of Patients with Major Depressive Disorder (MDD)”",
"Poster entitled “A 1-Year Open-label Study Assessing the Safety and Tolerability of Vilazodone in Patients with Major Depressive Disorder”",
"Poster entitled “Vilazodone Pharmacokinetics in Subjects with Mild to Moderate Renal Impairment”",
"Poster entitled “Vilazodone Pharmacokinetics in Subjects with Mild to Moderate Hepatic Impairment”",
"Poster entitled “In Vitro Characterization of Vilazodone as a Dual-Acting Serotonin Reuptake Inhibitor and 5-HT1A Receptor Partial Agonist”",
"Poster entitled “In Vivo and Ex Vivo Characterization of Vilazodone as a Serotonin Reuptake Inhibitor and 5-HT1A Receptor Partial Agonist”",
"Poster entitled “Electrophysiological Assessment of Accelerated 5-HT1A Autoreceptor Desensitization in Rats Produced by Vilazodone, a Novel Serotonin Reuptake Inhibitor and 5-HT1A Receptor Partial Agonist”"
05/24/2010 8-K Form 8-K - Current report
05/17/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Employment Agreement between Clinical Data, Inc. and James P. Shaffer"
02/09/2010 8-K Form 8-K - Current report
11/09/2009 8-K Form 8-K - Current report
10/28/2009 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Purchase Agreement by and between Clinical Data, Inc. and Piper Jaffray & Co., Wedbush Morgan Securities, Inc., BMO Capital Markets Corp. and Roth Capital Partners LLC",
"Opinion of Cooley Godward Kronish LLP",
"Clinical Data, Inc. Raises $47 Million in Public Offering of Common Stock"
09/09/2009 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Conference Presentation"
09/04/2009 8-K Form 8-K - Current report
08/10/2009 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Clinical Data, Inc. Reports First Quarter Fiscal 2009 Results"
08/05/2009 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Conference Presentation"
06/26/2009 8-K/A Financial Statements and Exhibits
06/15/2009 8-K Quarterly results
Docs: "Clinical Data, Inc. Reports Fourth Quarter and Fiscal Year 2009 Results — Transforms into a Drug Development Company with Late-stage Products — — Positive Results for Second Phase III Trial of Vilazodone in Treatment of Depression to Support NDA Filing this Year"
06/09/2009 8-K Form 8-K -- Current report
06/02/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression - On Track to File NDA This Year - - Conference Call to Discuss Results Today at 8:30 am EST -"
04/27/2009 8-K/A Form 8-K/A -- Current report [amend]
04/20/2009 8-K Asset disposition
Docs: "- PRESS RELEASE ISSUED BY CLINICAL DATA, INC. ON APRIL 14, 2009"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy